A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
作者： P. LoRusso , B. Markman , J. Tabernero , R. Shazer , L. Nguyen
DOI: 10.1200/JCO.2009.27.15_SUPPL.3502
关键词:
摘要: 3502 Background: XL765 is a potent and selective inhibitor of Class I PI3K isoforms, TORC1, TORC2. has shown dose-dependent target modulation tumor growth inhibition or shrinkage in m...
sci-hub.st 参考文章(0)